ASGCT 2025: Emerging Modalities for Oncology Treatments
BioPharm International® spoke with Ryan Larson, PhD, SVP, Head of Research at Umoja BioPharma about how emerging modalities in oncology treatments, including cell therapies, are evolving.
Oncology treatments are advancing quickly and encompass a range of promising areas, such as immune checkpoint inhibitors, antibody drug conjugates, T cell engagers, and in vivo chimeric antigen receptor (CAR) T-cell therapy, according to Ryan Larson, PhD, SVP, head of Research at Umoja BioPharma.
“We're seeing the continued transformative nature of cell therapies, in particular in hematologic malignancies, where you're seeing deep and durable responses continue in diffuse large B-cell lymphoma and other B-cell malignancies, as well as in multiple myeloma,” Larson says. “Yet access to ex vivo autologous cell therapies continues to be a challenge wherein a large fraction of patients that may be eligible for those therapies are not able to gain access to them for a variety of reasons."” Larson says.
Larson will be presenting “Current Advancements in In Vivo CAR T-cell Delivery” on Tuesday, May 13 at the 2025 American Society of Gene and Cell Therapy (ASGCT 2025), which is being held from May 13-17 in New Orleans.
Click the video above to watch the full interview.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
